FABP2 and metabolic dysfunction-associated steatotic liver disease: Evidence from this study suggests that I-FABP, L-FABP, and defensins 5 and 6 may not serve as potential early biomarkers for MASLD diagnosis, but they can be used to describe organ damage such as liver and intestinal damage in children with MASLD.